Bottom line
ETHSX vs IYH: the short answer
ETHSX (Eaton Vance Worldwide Health Sciences Fund) and IYH (iShares U.S. Healthcare ETF) are both mutual funds.
But IYH is far broader, holding 103 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
IYH is cheaper at 0.37% vs 1.18% — a difference of $81 a year per $10,000 invested.
Over five years, IYH returned +7.0% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
ETHSX vs IYH side by side
| ETHSX | IYH | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Morgan Stanley | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.18% | 0.37% |
| Annual cost per $10k | $118 | $37 |
| 10-yr cost on $10k (prospectus) | $1,911 | $468 |
| Max front load | 5.25% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −1.9% | +13.1% |
| 5-yr return (annualized) | +5.3% | +7.0% |
| 10-yr return (annualized) | +6.4% | +9.4% |
| Best quarter | +14.2% | +15.3% |
| Worst quarter | −12.1% | −12.7% |
| Net assets (fund) | $757.9M | $3.6B |
| Number of holdings | 42 | 103 |
| Portfolio turnover | 3% | 3% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | ETHSX | IYH | Difference |
|---|---|---|---|
| 2024 | +3.5% | +3.1% | +0.4% |
| 2023 | +5.7% | +2.1% | +3.6% |
| 2022 | −9.4% | −4.4% | −5.1% |
| 2021 | +22.1% | +23.4% | −1.3% |
| 2020 | +13.0% | +15.5% | −2.4% |
| 2019 | +26.0% | +20.8% | +5.2% |
| 2018 | +6.0% | +5.9% | +0.1% |
| 2017 | +16.2% | +22.3% | −6.1% |
| 2016 | −14.9% | −2.8% | −12.1% |
| 2015 | +8.4% | +6.1% | +2.3% |
Source: Fund prospectus bar charts
Holdings overlap
13 of ETHSX's top 25 holdings also appear in IYH's top 25.
| Holding | ETHSX | IYH |
|---|---|---|
| Eli Lilly & Co | 12.47% | 15.11% |
| AbbVie Inc | 6.46% | 7.32% |
| Johnson & Johnson | 6.45% | 10.17% |
| UnitedHealth Group Inc | 5.49% | 6.16% |
| Merck & Co Inc | 5.08% | 5.31% |
| Bristol-Myers Squibb Co | 4.25% | 2.20% |
| Vertex Pharmaceuticals Inc | 3.38% | 2.00% |
| Gilead Sciences Inc | 3.34% | 2.66% |
| Thermo Fisher Scientific Inc | 2.79% | 3.52% |
| Intuitive Surgical Inc | 2.72% | 2.05% |
| Stryker Corp | 2.21% | 1.86% |
| Boston Scientific Corp | 2.18% | 1.14% |
| Abbott Laboratories | 1.65% | 3.02% |
Source: SEC Form N-PORT
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
FAQ
What is the difference between ETHSX and IYH?
Which is cheaper, ETHSX or IYH?
Should I own both ETHSX and IYH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.